STATCenter·
STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
Read at STAT →
Health · 1 sources covering this
STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/e5315fd7e24cc1a35e84efa3ea7edcc746657da0" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study"></iframe>
